Related Experiment Video
Updated: Aug 12, 2026
Spheroid Assay to Measure TGF-β-induced Invasion
Published on: November 16, 2011
The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression
E Helseth1, G Unsgaard, A Dalen
1Department of Neurosurgery, University of Trondheim, Tronheim Regional Hospital, Norway.
Abstract:
Type beta transforming growth factor (B-TGF) is a potent growth inhibitor to many human tumor cell lines. Very little is known about the mechanism for this growth inhibitory action of B-TGF. We here report the effect of B-TGF on proliferation and epidermal growth factor receptor (R-EGF) expression in a human glioblastoma cell line named T-MG1. B-TGF inhibit the soft agar growth of T-MG1 cells. Maximum inhibition was 70%, achieved with 0.5 units B-TGF. B-TGF had no effect on monolayer growth of T-MG1 cells. T-MG1 cells contained abundant R-EGF, which could be divided into two subpopulations, one high affinity and one low affinity population of R-EGF. Treatment with B-TGF caused an initial decrease (0-6 h) in EGF-binding, followed by an increase in EGF-binding which reached maximum after 24 h exposure to B-TGF. Since addition of EGF to agar cultures gave no additional increase in inhibition by B-TGF and EGF alone had no inhibitory effect, we believe that binding of EGF to its receptor is not part of the pathway mediating the inhibitory effect of B-TGF. All neoplastic cells have lost some measure of growth control and the cellular elements involved are growth factors, growth factor receptors and oncogenes. T-MG1 cells contain abundant R-EGF and this may partly explain their malignant nature (malignant nature is here defined as ability to proliferate in agarose). Type alpha transforming growth factors, which in some cancer cells act as uncontrolled autocrine growth factors, were not found in protein extracts from T-MG1 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Type beta transforming growth factor (B-TGF) inhibits glioblastoma cell growth in soft agar. This study investigates B-TGF
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Type beta transforming growth factor (B-TGF) is a known inhibitor of many human tumor cell lines.
- The precise mechanisms underlying B-TGF's growth inhibitory actions remain largely unelucidated.
- Glioblastoma, a highly aggressive brain tumor, presents a significant challenge in cancer treatment.
Purpose of the Study:
- To investigate the effects of B-TGF on the proliferation and epidermal growth factor receptor (R-EGF) expression in the T-MG1 human glioblastoma cell line.
- To explore the potential role of R-EGF in mediating B-TGF's inhibitory effects.
- To understand the cellular mechanisms contributing to glioblastoma's malignant nature.
Main Methods:
- Culturing T-MG1 human glioblastoma cells.
- Assessing cell proliferation using soft agar and monolayer assays.
- Quantifying epidermal growth factor receptor (R-EGF) expression and binding affinity.
- Treating cells with varying concentrations of B-TGF and epidermal growth factor (EGF).
Main Results:
- B-TGF significantly inhibited soft agar growth of T-MG1 cells, with maximum inhibition of 70% at 0.5 units.
- B-TGF did not affect monolayer growth of T-MG1 cells.
- B-TGF treatment altered EGF-binding to T-MG1 cells, causing an initial decrease followed by an increase.
- EGF addition did not enhance B-TGF's inhibitory effect, suggesting EGF receptor binding is not the primary mediation pathway.
Conclusions:
- B-TGF effectively inhibits the anchorage-independent growth of T-MG1 glioblastoma cells.
- The mechanism of B-TGF inhibition does not appear to involve direct modulation of EGF receptor binding.
- Abundant R-EGF in T-MG1 cells may contribute to their malignant phenotype, characterized by the ability to proliferate in agarose.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:16TGF - β Signaling Pathway